These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort. Shireman TI; Rigler SK Am J Geriatr Pharmacother; 2006 Sep; 4(3):210-8. PubMed ID: 17062321 [TBL] [Abstract][Full Text] [Related]
43. Impact of compliance with proton pump inhibitors on NSAID treatment. Duh MS; Gosselin A; Luo R; Lohoues H; Lewis BE; Crawley JA Am J Manag Care; 2009 Oct; 15(10):681-8. PubMed ID: 19845420 [TBL] [Abstract][Full Text] [Related]
44. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Chan FK; Abraham NS; Scheiman JM; Laine L; Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980 [TBL] [Abstract][Full Text] [Related]
46. [Prevention of NSAID gastropathy: the difference between a coxibs and the addition of a PPI]. Lems WF; Kuipers EJ Ned Tijdschr Geneeskd; 2010; 154(45):A2663. PubMed ID: 21118596 [TBL] [Abstract][Full Text] [Related]
48. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Chancellor JV; Hunsche E; de Cruz E; Sarasin FP Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106 [TBL] [Abstract][Full Text] [Related]
49. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785 [TBL] [Abstract][Full Text] [Related]
50. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Laine L Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071 [TBL] [Abstract][Full Text] [Related]
51. Prevention and treatment of NSAID-induced gastroduodenal injury. Lanas A Curr Treat Options Gastroenterol; 2006 Apr; 9(2):147-56. PubMed ID: 16539875 [TBL] [Abstract][Full Text] [Related]
52. The prevention of gastropathy and upper abdominal symptoms caused by nonsteroidal anti-inflammatory drugs. Vakil N Rev Gastroenterol Disord; 2006; 6(4):221-6. PubMed ID: 17224894 [TBL] [Abstract][Full Text] [Related]
53. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Yang M; Wang HT; Zhao M; Meng WB; Ou JQ; He JH; Zou B; Lei PG Medicine (Baltimore); 2015 Oct; 94(40):e1592. PubMed ID: 26448006 [TBL] [Abstract][Full Text] [Related]
54. [Adherence with proton pump inhibitor therapy, by continuously taking nonsteroidal anti-inflammatory drugs]. Pimanov SI; Makarenko EV; Dikareva EA Ter Arkh; 2015; 87(4):58-61. PubMed ID: 26087636 [TBL] [Abstract][Full Text] [Related]
56. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy]. Lanas A Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979 [TBL] [Abstract][Full Text] [Related]
57. Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. Van der Linden MW; Gaugris S; Kuipers EJ; Van den Bemt BJ; van Herk-Sukel MP; Herings RM Curr Med Res Opin; 2009 Jan; 25(1):195-204. PubMed ID: 19210152 [TBL] [Abstract][Full Text] [Related]
58. Nonsteroidal anti-inflammatory drugs versus selective COX-2 inhibitors in the upper gastrointestinal tract. Schölmerich J J Cardiovasc Pharmacol; 2006; 47 Suppl 1():S67-71. PubMed ID: 16785832 [TBL] [Abstract][Full Text] [Related]
59. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis. Inotai A; Mészáros A Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498 [TBL] [Abstract][Full Text] [Related]
60. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs. Thomas D; Ali Z; Zachariah S; Sundararaj KGS; Van Cuyk M; Cooper JC Am J Cardiovasc Drugs; 2017 Oct; 17(5):343-346. PubMed ID: 28353025 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]